A practical reference on intranasal route: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-05-16 and is reviewed periodically as new material appears.
Published research has focused mainly on neurological and cognitive endpoints in animal models, with proposed mechanisms involving brain-derived neurotrophic factor and related signalling pathways. A substantial share of the human data originates from a limited number of research groups, and independent replication in other countries remains sparse. Regulatory status reflects that distribution: the peptide is registered as a medicine in Russia and appears in some neighbouring markets, while elsewhere it is handled as a research chemical without approved therapeutic labelling. Questions about dose-response relationships, long-term effects, and comparability across studies are still open.
Lyophilised powder is normally kept at -20 °C in a desiccated container, with some suppliers recommending -80 °C for long-term archival storage. Repeated freeze-thaw cycles are the most common cause of avoidable loss, so aliquoting before freezing reduces variability between working sessions. Dissolved peptide is far less stable than the dry solid and is usually prepared fresh or held briefly at 4 °C. Aqueous solutions support both hydrolysis of the backbone and oxidation of the N-terminal methionine, and these two routes dominate degradation under ordinary laboratory conditions.
Identity and purity are confirmed with reversed-phase high-performance liquid chromatography, typically monitored at 214 nanometres where the peptide bond absorbs. Mass spectrometry, either electrospray or MALDI-TOF, verifies molecular mass against the theoretical value and detects truncation or adduct formation. Amino acid analysis and peptide mapping provide additional confirmation when required. The most frequently reported impurities are deletion sequences from incomplete coupling, methionine sulfoxide from oxidation, and dimeric species formed through non-covalent aggregation. Impurity profiles depend strongly on the synthesis and purification route chosen by the producer.
Regulatory status differs sharply between jurisdictions. In Russia the peptide is registered as a prescription nasal preparation, while agencies such as the United States Food and Drug Administration have not approved it for any indication. Products sold elsewhere are typically labeled for laboratory research only, and such labels shift responsibility for safe handling to the purchaser. Because the same name covers pharmaceutical-grade nasal drops and bulk research powder, identity and purity documentation becomes the main practical concern when comparing sources.
Semax is a synthetic seven-amino-acid peptide whose sequence extends the ACTH(4-10) fragment with a C-terminal proline-glycine-proline tripeptide. The commonly cited sequence is Met-Glu-His-Phe-Pro-Gly-Pro, giving a molecular formula near C37H51N9O10S and a molecular weight close to 813.9 g/mol. It belongs to the broader class of synthetic ACTH fragments studied for central nervous system effects rather than for adrenal steroid stimulation. In practice the material appears as a lyophilized white powder for laboratory work or as a dilute saline solution in clinical settings.
Development is attributed to researchers at the Institute of Molecular Genetics in Moscow during the early 1980s, building on earlier Soviet work with ACTH fragments. Russian regulatory approval followed for intranasal use, and the compound has remained commercially available there for decades. Most published human data originate from Russian and, later, some Eastern European clinical reports, which are not always accessible in English translation. Outside that region the material is generally handled as a research chemical rather than a licensed medicine.
| Property | Value | Notes |
|---|---|---|
| Purity assay | RP-HPLC, UV 214 nm | Typical research grade 95 percent or higher |
| Mass confirmation | ESI-MS or MALDI-TOF | Compared with theoretical value |
| Main degradation route | Methionine oxidation | Sulfoxide formation in solution |
| Powder storage | -20 °C, desiccated | Amber vial, minimal headspace |
| Working solution | Sterile water or saline | Prepare fresh; avoid repeated thawing |
Solid material is normally kept at minus 20 degrees Celsius in a sealed, desiccated container. Reconstituted solutions are less stable and are usually divided into single-use aliquots before freezing. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of activity. Light exposure is minimized by using amber glassware or foil wrapping. Published stability data for this peptide are sparse, so recommended storage conditions rest mainly on general practice for short synthetic peptides rather than on dedicated study.
Identity and purity are commonly assessed by reversed-phase high-performance liquid chromatography, with ultraviolet detection near 214 nanometers for the peptide backbone. Mass spectrometry, either electrospray or matrix-assisted laser desorption, confirms molecular mass and detects truncation or modification products. Amino acid analysis can verify composition. Because the sequence contains no strongly absorbing aromatic residue apart from phenylalanine, detection wavelengths are chosen carefully. Purity values above 95 percent are typical for research-grade material.
Quality documentation for research-grade peptide usually includes a certificate of analysis stating purity, identity, and residual counterion content. Batch-to-batch variation in purity and salt form is a recognized issue, and comparisons across suppliers require attention to the exact counterion, for example acetate versus trifluoroacetate. Sequence verification by tandem mass spectrometry provides stronger evidence than a single mass measurement. For any study reporting biological results, the analytical method and the measured purity should be stated explicitly. Independent verification of supplier claims is considered good practice.
Reported pharmacological work centers on neurotrophic signaling, including changes in BDNF and NGF expression in hippocampal tissue in animal models. Human data come largely from studies conducted in Russia, and how well those results generalize to other populations remains an open question. Regulatory status differs sharply by jurisdiction: Semax is a registered prescription medicine in Russia, while it holds no approved marketing status in the United States or the European Union. Outside such jurisdictions it is generally handled as a research chemical, which affects both documentation and quality expectations.
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. It was developed as a fragment analog of adrenocorticotropic hormone, modeled specifically on the ACTH(4-10) region. The first four residues reproduce that fragment, while a Pro-Gly-Pro tripeptide is appended at the C-terminus. Work on the compound originated in Russia, where it entered clinical use as an intranasal preparation. Its sequence places it among short regulatory peptides studied for effects on the central nervous system rather than on the adrenal axis.
The C-terminal Pro-Gly-Pro extension is not incidental. Proline-rich tails are known to resist several common peptidases, and the published literature attributes the longer half-life of Semax, relative to unmodified ACTH fragments, to this feature. The modification also removes the melanocyte-stimulating and corticosteroidogenic activity that characterizes longer ACTH-derived sequences. Because the molecule is small and hydrophilic, it is typically formulated as an aqueous solution for intranasal or parenteral delivery. Acetylation or amidation at the termini appears in closely related research peptides and shifts the mass by a fixed increment.
Published research covers ischemic stroke, traumatic brain injury, cognitive impairment, optic nerve conditions and attention-related measures. Much of the human evidence comes from small trials conducted in one country, which limits how far the results generalize. Animal models supply the larger share of the data, and effects seen in rodents do not transfer automatically to people. Reviews have noted that methodological reporting is often incomplete, making it difficult to pool results or compare treatment schedules across studies.
Pharmacokinetic accounts emphasize rapid breakdown. After intravenous dosing the intact peptide disappears from blood within minutes, and nasal delivery produces low but measurable concentrations. Metabolites rather than the parent molecule may account for part of the observed activity, although the relative contribution is unresolved. Dosing in the literature varies widely and no optimal schedule has been agreed. These gaps are regularly cited as a reason the findings have not produced broad clinical adoption beyond the original research setting.
Proposed mechanisms center on neurotrophic signaling rather than on classical melanocortin receptor activation. Rodent experiments have reported shifts in the expression of brain-derived neurotrophic factor and nerve growth factor after administration, together with changes in the associated receptor systems. Several authors argue that the peptide acts largely through its degradation products and their interaction with peptidergic pathways, but this remains a hypothesis rather than a settled finding. No single molecular target has been identified in a way that the field broadly accepts.
Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
Kardashev first outlined his scale in a paper presented at the 1964 conference that communicated findings on BS-29-76, the Byurakan Conference in the Armenian SSR, which reviewed the Soviet radio astronomy space listening program. The paper was titled "Передача информации внеземными цивилизациями" or Transmission of Information by Extraterrestrial Civilizations. The paper was published in 1964 first in Russian in the March–April issue of the Astronomicheskii Zhurnal, then in English in the September–October 1964 issue of the Soviet Astronomical Journal. In it, the scientist presents a calculation of the evolution of the power needs of humanity. Assuming that overall human power use will continue to increase, he calculates that the rate of energy consumption will cross specific mileposts. Kardashev proposed a typology of technological civilizations based on the evolutive attainment of the three power harnessing mileposts he described. A civilization known as "Type I" has achieved a technological level close to the one attained on Earth at the time Kardashev's article was submitted (December 1963), with a rate of energy consumption evaluated at about 4×1012 watts (W). A civilization known as "Type II" would surpass the first by fourteen orders of magnitude, matching the entire power emitted by the Sun in about 3,200 years, i.e., Earth's home star's "output" at that time, predicted at 4×1026 W.
== Notable popular press work == "Standing Strong", Cancer Today - 2013 "The Future of Election Forecasting", Scientific American - 2014 "Regrown nerves boost bionic ears", Nature - 2014 "How scientists fool themselves - and how they can stop", Nature - 2015 "What Happens When Scientists Experiment on Themselves?" - Reader's Digest - 2016 "When courtroom science goes wrong - and how stats can fix it", Knowable Magazine - 2018
====== Glycerin ====== Glycerin (often called vegetable glycerin, or VG) was long thought to be a safe option. However, the carcinogen formaldehyde is known as an impurity found in propylene glycol and glycerol vapor degradation.
The disease was first described by the Neapolitan physician Giovanni Semmola in 1834 and Gaetano Conte in 1836. However, Duchenne muscular dystrophy is named after the French neurologist Guillaume-Benjamin-Amand Duchenne (1806–1875), who in the 1861 edition of his book Paraplégie hypertrophique de l'enfance de cause cérébrale, described and detailed the case of a boy who had this condition. A year later, he presented photos of his patient in his Album de photographies pathologiques. In 1868, he gave an account of 13 other affected children. Duchenne was the first to do a biopsy to obtain tissue from a living patient for microscopic examination.
1993/821) Hinchingbrooke Health Care National Health Service Trust Dissolution Order 1993 (S.I. 1993/822) Hinchingbrooke Health Care National Health Service Trust (Establishment) Order 1993 (S.I. 1993/823) Reconstitution of the Upper Medway Internal Drainage Board Order 1993 (S.I. 1993/824) Reconstitution of the Lower Medway Internal Drainage Board Order 1993 (S.I. 1993/825) National Rivers Authority (Severn-Trent Region) (Reconstitution of the Newark Area Internal Drainage Board) Order 1993 (S.I. 1993/829) Non-Domestic Rates (No.2) (Scotland) Order 1993 (S.I. 1993/830) Medicines (Applications for Manufacturer's and Wholesale Dealer's Licences) Amendment Regulations 1993 (S.I. 1993/832) Medicines (Standard Provisions for Licences and Certificates) Amendment Regulations 1993 (S.I. 1993/833) Medicines Act 1968 (Amendment) Regulations 1993 (S.I. 1993/834) Education (Individual Pupils' Achievements) (Information) (Wales) Regulations 1993 (S.I. 1993/835) Banking Act 1987 (Disclosure of Information) (Specified Persons) (Revocation) Order 1993 (S.I. 1993/836) Education (Grant-maintained Schools) (Finance) (Amendment) Regulations 1993 (S.I. 1993/843) Social Security (Miscellaneous Provisions) Amendment Regulations 1993 (S.I. 1993/846) The Official Secrets Act 1989 (Prescription) (Amendment) Order 1993 (S.I. 1993/847) Local Government (Direct Service Organisations) (Competition) Regulations 1993 (S.I. 1993/848) Calderdale and Kirklees (Metropolitan Borough Boundaries) Order 1993 (S.I. 1993/850) Bolton and Salford (City and Metropolitan Borough Boundaries) Order 1993 (S.I.
Sources: en.wikipedia.org
from arginine via nitric oxide synthase, as a byproduct of the production of nitric oxide for signaling purposes from ornithine through the breakdown of proline or glutamine/glutamate from asymmetric dimethylarginine via DDAH Citrulline is made from ornithine and carbamoyl phosphate in one of the central reactions in the urea cycle. It is also produced from arginine as a byproduct of the reaction catalyzed by NOS family (NOS; EC 1.14.13.39). It is also prevalent in trichohyalin at the inner root sheath and medulla of hair follicles, where it is synthesized from arginine. Arginine is first oxidized into N-hydroxyl-arginine, which is then further converted to citrulline concomitant with release of nitric oxide.
=== Reverse transcriptase can copy RNA into DNA === Retroviruses were shown to have a single-stranded RNA genome and to replicate via a DNA intermediate, the reverse of the usual DNA-to-RNA transcription pathway. They encode a RNA-dependent DNA polymerase (reverse transcriptase) that is essential for this process. Some retroviruses can cause diseases, including several that are associated with cancer, and HIV-1 which causes AIDS. Reverse transcriptase has been widely used as an experimental tool for the analysis of RNA molecules in the laboratory, in particular the conversion of RNA molecules into DNA prior to molecular cloning and/or polymerase chain reaction (PCR).
=== Gun laws === Sanders supports closing the "gun show loophole", banning assault weapons, and passing and enforcing universal federal background checks for gun purchases. In 1990, his bid to become a US Representative benefitted from the National Rifle Association of America opposing the competing campaign of Peter Smith, who had reversed his stance on firearm restrictions, and waiting periods for handgun purchases. In 1993, while a US representative, he voted against the Brady Handgun Violence Prevention Act (which established background checks and wait periods), and in 2005 voted for legislation that gave gun manufacturers legal immunity against claims of negligence, but as of 2016 he has since said that he would support repealing that law. In 1996, he voted against additional funding to the Centers for Disease Control and Prevention for research on issues related to firearms, but in 2016, he called for an increase in CDC funding for the study of gun violence.
== Development == PMCA was originally developed to, in vitro, mimic prion replication with a similar efficiency to the in vivo process, but with accelerated kinetics. PMCA is conceptually analogous to the polymerase chain reaction - in both systems a template grows at the expense of a substrate in a cyclic reaction, combining growing and multiplication of the template units.
== Technology description == All living surfaces are decorated with a diverse range of complex molecules, which are key modulators of chemical communications and other functions such as protection, adhesion, infectivity, apoptosis, etc. Functional-Spacer-Lipid (FSL) Kode constructs can be synthesized to mimic the bioactive components present on biological surfaces, and then re-present them in novel ways. The architecture of an FSL Kode construct, as implicit in the name, consists of three components - a functional head group, a spacer, and a lipid tail. This structure is analogous to a Lego minifigure in that, they have three structural components, with each component having a separate purpose. In the examples shown in all the figures, a Lego 'minifig' has been used for the analogy. However, it should be appreciated that this is merely a representation and the true structural similarity is significantly varied between Lego minifigures and FSL Kode constructs (fig 1). The functional group of an FSL is equivalent to a Lego minifigure head, with both being at the extremity and carrying the character functional components. The spacer of the FSL is equivalent to the body of the Lego minifigure and the arms on the minifigure are representative of substitutions which may be engineered into the chemical makeup of the spacer. The lipid of the FSL anchors it to lipid membranes and gives the FSL construct its amphiphatic nature which can cause it to self-assemble. Because the lipid tail can act directly as an anchor it is analogous to the legs of a Lego minifigure.
Sources: en.wikipedia.org
Reversed-phase HPLC gives the main purity figure, most often with UV detection near 214 nanometres. Mass spectrometry then confirms the molecular mass. Together the two methods distinguish a correct sequence from a closely related impurity.
The main chemical risks are methionine oxidation and backbone hydrolysis in solution. Moisture and repeated temperature cycling accelerate both processes. Dry powder held cold and desiccated is considerably more stable than any reconstituted preparation.
It holds a medicine registration in Russia, where it has been used clinically for decades. In most other countries it is treated as a research chemical. That split explains the uneven distribution of clinical literature.
It is a short synthetic peptide built from seven amino acids: methionine, glutamic acid, histidine, phenylalanine and three prolines. The sequence derives from the 4-10 fragment of adrenocorticotropic hormone with an added proline-glycine-proline tail. No plant or animal extract is involved; the material is produced by solid-phase peptide synthesis.